FDA Fast-Tracks an Ozempic-Class Drug for Alcohol Use Disorder

A drug from the same class that reshaped obesity care just got a regulatory green light to try the same thing for the most undertreated addiction in America.

On August 5, the FDA granted Fast Track designation to pemvidutide for the treatment of alcohol use disorder. Fast Track isn’t approval. It’s a status the FDA gives drugs aimed at serious, underserved conditions, and mostly it means the agency will review a company’s data in pieces as they arrive instead of making everyone wait for one complete package at the end. It can get a promising drug to patients faster — if the science holds up. It says nothing yet about whether the science will hold up.

The number that makes this matter more than a routine pipeline update: only 2.6% of Americans with past-year alcohol use disorder are on any medication for it, according to SAMHSA’s newly released 2025 National Survey on Drug Use and Health — one of the widest treatment gaps in addiction medicine.

That same survey counted 25.7 million Americans with alcohol use disorder in the past year. Three medications are already FDA-approved for it — naltrexone, acamprosate, disulfiram — all decades old, and clinicians widely consider them underprescribed, inconsistently effective, and burdened by side effects or logistics that push people away before they start (disulfiram makes you ill if you drink; acamprosate is three pills a day, indefinitely). The result: 97.4% of people who meet criteria for alcohol use disorder get zero pharmacological help. Not because nothing exists. Because what exists hasn’t been good enough, or accessible enough, to reach them.

Pemvidutide, developed by Altimmune, is a dual GLP-1/glucagon receptor agonist — a drug that activates two separate hormone pathways involved in appetite and metabolism at once, the same broad family as Ozempic and Wegovy, engineered to hit both receptors instead of one. It’s currently in a Phase 2 trial called RECLAIM, testing roughly 100 participants on weekly injections against placebo over 24 weeks, tracking whether it reduces heavy drinking days. The trial isn’t finished. There is no human efficacy data yet to point to for this indication — the Fast Track designation is a bet on unmet need and biological plausibility, not a verdict on results.

Altimmune’s president and CEO, Vipin Garg, made the stakes explicit when the designation was announced: “Despite an estimated prevalence of AUD in more than 28 million adults in the U.S. alone, the scarcity of effective treatment options has created a sizeable treatment gap in AUD, with only 2% being treated with medication today.” His figure and SAMHSA’s independent count land in the same place from two different directions.

This isn’t an isolated bet, either. GLP-1-class drugs are already being studied for alcohol use disorder at academic medical centers and inside the VA, entirely apart from this one trial. That’s the larger story: a drug class built to treat obesity has become the most active site of new pharmacological research for a condition medicine has left mostly untreated for decades, not from lack of need but from lack of tools people would actually use.

Whether pemvidutide turns out to be one of those tools is still unknown. That so few tools currently exist is not.